

### **CUIMC Research Pharmacy** Milstein Hospital Building 177 Fort Washington Avenue Suite MHB-LL1 New York, NY 10032 212.305.9867 Tel 212.305.0068 Fax

## **COST ESTIMATE REQUEST FORM**

Please complete the entire form so the Research Pharmacy may provide you with a cost estimate. Return the completed form to researchpharmacy@columbia.edu as an e-mail attachment or fax to 201-305-0068. Include a copy of the protocol if not submitted prior.

IRB #	(if available)		
<b>Contact Information:</b>			
Investigator:	Phone:		
Fax:	E-mail:		
Coordinator:	Phone:		
Fax:	E-mail:		
Administrator:	Phone:		
Fax:	E-mail:		
	point-of-contact for receiving study invoices and billing information, please list this same		
Study Title:			
<b>Study Description:</b> (check all that a	apply)   Inpatient  Outpatient  Multicenter		

# \*\*\*A study is considered on call if there is a possibility for dispensing outside of normal business hours (M-F 8AM-4PM). There is an additional fee for this service. \*\*\*

### Department:

- □ Biochemistry & Molecular Biophysics
- □ Biomedical Informatics
- Dental Medicine
- □ Dermatology
- Genetics & Development
- □ Medicine Cardiology
- □ Medicine Digestive & Liver Disease
- □ Medicine Endocrinology
- □ Medicine Experimental Therapeutics
- □ Medicine General Medicine
- □ Medicine Hematology
- □ Medicine Infectious Disease
- □ Medicine Molecular Medicine
- □ Medicine Nephrology
- □ Medicine Oncology
- □ Medicine Preventive Medicine & Nutrition
- □ Medicine Pulmonary, Allergy & Critical Care
- □ Medicine Rheumatology
- □ Microbiology & Immunology
- □ Neurology
- $\Box$  Neuroscience
- □ Neurosurgery
- □ Obstetrics and Gynecology
- □ Ophthalmology
- □ Orthopedic Surgery
- □ Otolaryngology / Head & Neck Surgery
- □ Pathology
- □ Anesthesiology
- □ ICAP

- Pediatrics General
  Pediatrics Hematology
  Pediatrics Infectious Disease
  Pediatrics Molecular Genetics
  Pediatrics Neonatology
  Pediatrics Nephrology
  Pediatrics Neurology
  Pediatrics Oncology
  Pediatrics Pulmonary
  Pediatrics Rheumatology
  Pharmacology
  Physiology and Cellular Biophysics
  Psychiatry
- □ Mailman School of Public Health
- □ Radiation Oncology

□ Pediatrics - Allergy

□ Pediatrics - Cardiology

**D** Pediatrics - Critical Care

D Pediatrics - Education

□ Pediatrics - BMT

□ Pediatrics - Biomathematics

□ Pediatrics - Clinical Genetics

□ Pediatrics - Emergency Med

□ Pediatrics – Gastroent. & Nutrition

□ Pediatrics - Endocrinology

- □ Rehabilitation Medicine
- □ Surgery
- □ Urology
- □ Emergency Medicine

#### **Funding Source:**

Sponsor: □ Investigator Initiated □ Pharmaceutical Industry Sponsor	□SWOG	□CCG	□COG	
Spon Name	 _Spon Prot #			 
Spon ContactName	 Phone			 

Fax:\_\_\_\_\_E-mail:\_\_\_\_\_

<u>Services requested:</u> (check all that apply)

<i>Dispense:</i> □ Capsules/Tablet	Patient Kit	□ IV Product	□ Pre-filled Syringes
------------------------------------	-------------	--------------	-----------------------

□ Ointment/Cream □Other\_\_\_\_\_

## Delivery: (There is an additional fee for this service)

Are deliveries to hospital or clinic sites required?  $\Box$  Yes  $\Box$ No

If yes, specify delivery location(s) (Building, Flr, Rm)

Where will patients be seen (Clinic location)?

*Drug Product Ordering:* □Yes □ No (Investigator must complete Drug Requisition Form Attached)

*Drug Returns:* (Investigator, if unsure, check with study sponsor): □ No drug returns to Research Pharmacy, Investigator will oversee drug return and destruction via OSHA, EPA, DEA compliant methods

Used drug supplies will be returned to Research Pharmacy for immediate destruction

 $\Box$  Used drug supplies will be returned to Research Pharmacy for storage and reconciliation by study monitor, and then destruction or return to sponsor

 $\Box$  Used drug supplies generated in the pharmacy must be stored in the Research Pharmacy for reconciliation by study monitor, and then destruction or return to sponsor

### Randomization:

□ There is no randomization

□ Randomization will be managed by the Investigator and the Research Pharmacy will be notified of treatment assignment in writing on drug order or via separate FAX

□ Randomization will be managed by the Research Pharmacy via an Interactive Voice Recognition System (IVRS)

□ Randomization will be generated by the sponsor or Investigator and managed by the Research Pharmacy via paper copy or on-line randomization method

□ Randomization code will be generated by the Research Pharmacy managed within the Research Pharmacy

### Inventory:

□ Inventory will be handled by the Research Pharmacy using standard GCP compliant methods

□ Inventory will be handled by the Research Pharmacy using Sponsor specific inventory forms

 $\Box$  Inventory will be handled by the Research Pharmacy using Sponsor specific inventory forms and IVRS

Drug Description: Anti-N	oplastic Agent(s)?	□Yes	□No
--------------------------	--------------------	------	-----

*Study Drugs:* (include both investigational agents and FDA approved products)

Study drug provider:
<i>Formulation:</i> (check all that apply) □ Capsules □Tablet □Vials □Pre-Packaged For Dispensing □ Bulk (Requires Packaging/Labeling/Dispensing)
<i>Storage:</i> (check all that apply) $\square$ Room temp $\square 2-8^{\circ}C$ $\square < -10^{\circ}C$ $\square \le -70^{\circ}C$ $\square$ Other
Additional Items/Equip Required:  IV Pump Injection supplies Ordering Bulk Drug
Other
Items/equipment provider:
Additional Info: Has Project been submitted to IRB?  Yes  No
Will study be submitted to the Clinical Trials Office?
Anticipated Start Date:Approx duration:
Estimated # of patients

### Monitoring:

□ Investigator will monitor Research Pharmacy function directly without outside monitoring

□ Sponsor will not monitor Research Pharmacy function				
□ Sponsor will monitor Research Pharmacy function				
Monitoring performed by: $\Box$ Sponsor $\Box$ CRO/SRO $\Box$ C	Other			
Monitoring Company Name/Div				
Monitor NamePhone				
Fax:E-mail:				

The following number of outside monitoring visits are expected each year\_\_\_\_\_

Effective February 1st, 2022, a new fee schedule has been implemented. This is applicable for all cost estimate requests submitted to the research pharmacy on or after February 1st, including new studies related to prior ones, such as studies involving subsequent phases or long-term monitoring. The prior fee schedule will continue to be honored for studies that are active prior to February 1st, 2022.

Invoices will be e-mailed to the Principal Investigator for pre-approval. Invoices may also be e-mailed to one (1) additional person named as Principal Investigator Designee, if desired. If you wish to name a Principal Investigator Designee for this protocol, please provide us with the following.

Name of "Principal Investigator Designee"	Email

The listed "Principal Investigator Designee" will be the point-of-contact for receiving study invoices and billing information. If this information changes throughout the duration of study, please email IDS-Billing@columbia.edu

# The Research Pharmacy will not provide services until the signed cost estimate and regulatory documents (IRB approval letter, 1572 form) have been received.

When you are ready to initiate the study, please notify the Research Pharmacist named on the cost estimate.

Thank you.